Eventide Asset Management, LLC Uni Qure N.V. Transaction History

Eventide Asset Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 13, 2020	SELL	$35.98 - $47.66 $18 Million - $23.8 Million	-500,000 Closed	0 $0
Q3 2019 Nov 21, 2019	BUY	$39.36 - $76.8 $9.45 Million - $18.4 Million	240,000 Added 92.31%	500,000 $19.7 Million
Q2 2019 Aug 14, 2019	SELL	$52.76 - $82.19 $14.7 Million - $22.9 Million	-278,700 Reduced 51.74%	260,000 $20.3 Million
Q1 2019 May 15, 2019	SELL	$27.39 - $68.41 $5.41 Million - $13.5 Million	-197,509 Reduced 26.83%	538,700 $32.1 Million
Q4 2018 Feb 14, 2019	BUY	$22.8 - $33.93 $3.8 Million - $5.65 Million	166,509 Added 29.23%	736,209 $21.2 Million
Q3 2018 Nov 14, 2018	SELL	$29.75 - $43.08 $5.48 Million - $7.94 Million	-184,350 Reduced 24.45%	569,700 $20.7 Million
Q2 2018 Aug 14, 2018	BUY	$21.96 - $39.94 $9.2 Million - $16.7 Million	419,050 Added 125.09%	754,050 $28.5 Million
Q1 2018 May 15, 2018	BUY	$17.1 - $26.61 $5.73 Million - $8.91 Million	335,000 New	335,000 $7.87 Million

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Eventide Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Eventide Asset Management, LLC with notifications on news.